Picture Berlin Partner Bionnale 2023 the Life Sciences Event 650x100px
Document › Details

BioGeneration Ventures B.V.. (1/17/23). "Press Release: BGV Appoints Jaap de Bruin as FIRST Fund Investment Manager and Promotes Rianne Ellenbroek to Principal". Amsterdam.

Organisations Organisation FIRST (Fonds InvesteringsRijpe STarters) (BGV FIRST Fund)
  Group BioGeneration Ventures B.V. (BGV)
  Organisation 2 Utrecht Health Seed Fund (HSF)
  Group University of Utrecht (Utrecht University)
Products Product venture capital
Persons Person de Bruin, Jaap (BioGeneration Ventures 202301– Investment Manager at FIRST Fund before Utrecht Health Seed Fund)
  Person 2 Ellenbroek, Rianne (BioGeneration Ventures 202301– promoted to Principal joined 2020 before Inkef Capital)

BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma, today announces the appointment of Jaap de Bruin as Investment Manager, leading BGV’s Fonds InvesteringsRijpe Starters (FIRST) fund, taking over from Rianne Ellenbroek who is promoted to Principal for BGV funds.

Jaap de Bruin joins BGV from Utrecht Health Seed Fund where he was Fund Manager, overseeing a series of successful investments in health and life sciences companies such as TargED Biopharmaceuticals, NTrans Technologies and Moveshelf. Prior to this, Jaap was an Investment Manager and Senior Business Developer at Utrecht Holdings where he led a number of investments, including the investment in Quantib, which was successfully sold to RadNet, Inc. He directed over 15 intellectual property tech license deals including the MR-STAT technology to Philips Healthcare. Prior to this, Jaap held several roles at Philips Healthcare’s Image Guided Therapy business and corporate incubator. Jaap holds a master’s degree in Aerospace Engineering from Delft University of Technology.

Rianne is an experienced life science professional with more than 5 years of experience in venture capital. She joined BGV in 2020 as Investment Manager of the FIRST fund, helping to establish the fund and overseeing the completion of its initial investments, most notably that of TargED Biopharmaceuticals, which subsequently raised €39 million in its Series A fundraising.

Prior to joining BGV, she was an Associate at INKEF Capital. In her new role as Principal, Rianne will work across all BGV funds while continuing to support the FIRST fund. Rianne is a medical biologist by training and during her academic career, she worked at Leiden University, University of Chicago and Galapagos. She holds a PhD from Leiden University in regenerative medicine.

Jaap de Bruin, the new Investment Manager at BGV commented: “BGV is a leading investor and partner in Europe, and I am thrilled to be joining a team of such experienced and knowledgeable life sciences experts. I look forward to building on the strong foundations of the FIRST fund and to continuing its work pioneering science at the earliest stages.”

Edward van Wezel, Managing Partner of BGV noted: “Jaap brings a great deal of experience and an impressive track record of skilled portfolio management, and I look forward to working closely with him as he takes up his role for our FIRST fund. We are also pleased to promote Rianne to the position of Principal. She played an instrumental role within the FIRST fund, and we are confident that we will see her impact across the other BGV’s portfolio.”


For more information please contact:

Media Enquiries
Laura Asbjornsen, Head of Communications
Tel: +31 (0)35 699 30 00

Consilium Strategic Communications
Ashley Tapp, Sue Charles
Tel: +44 (0)20 3709 5700

About BGV

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. With a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies, BGV manages over EUR 250 million of funds and invests in areas where true scientific innovations, unmet medical needs, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to progress science and build successful companies and uses its experience to guide progress into clinical trials, leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. The Company is based in Naarden, The Netherlands. For more information, please visit:

Record changed: 2023-01-17


Picture [iito] No Tracking 650x100px

More documents for BioGeneration Ventures B.V. (BGV)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner Join Cluster HealthCapital Berlin Brandenburg 650x300px

» top